Medtronic, Portsmouth, NH, USA.
Plastic Surgery Private Practice, San Francisco, CA, USA.
Ann Surg Oncol. 2018 Dec;25(13):3867-3873. doi: 10.1245/s10434-018-6760-7. Epub 2018 Sep 21.
Oncoplastic breast surgery aims to optimize efficacy of surgical resection and cosmesis to maximize patient satisfaction; however, despite the benefits, oncoplastic techniques have not been widely adopted in the US. This study examined trends in the incidence of lumpectomy (partial mastectomy) with or without oncoplastic techniques from 2011 to 2016.
This was a retrospective analysis of claims from the Optum Clinformatics database (January 2010-March 2017). Female patients with no history of breast surgery in the prior year were categorized into three independent cohorts: isolated lumpectomy (Lx), lumpectomy with tissue transfer (LxTT), or lumpectomy with mammaplasty and/or mastopexy (LxMM). Oncoplastic techniques (in cohorts two and three) were performed at either time of the initial lumpectomy or during 90-day follow-up.
Overall, 19,253 patients met the inclusion criteria (91.1% Lx, 5.2% LxTT, and 3.7% LxMM). Significantly fewer patients with Lx had a family history of breast cancer compared with patients with oncoplastic techniques (26.4% vs. 33.7% and 37.9%, respectively; p < 0.001). The incidence of Lx declined significantly from 2011 (92.9%) to 2016 (88.1%), while LxTT and LxMM increased from 4.2 to 7.2% and 2.8 to 4.7%, respectively (both p < 0.001). The greatest utilization of oncoplastic techniques was observed in the Pacific census division (19.2%), while lowest utilization was in the East South Central division (3.2%; p < 0.001).
While increased adoption of oncoplastic techniques was observed, the compound annual growth rate remained below 10% and varied significantly by region. Further adoption of oncoplastic techniques is necessary to improve cosmetic outcomes and patient satisfaction following breast-conserving surgery.
肿瘤整形乳房切除术旨在优化手术切除的疗效和美容效果,以最大限度地提高患者满意度;然而,尽管有这些益处,肿瘤整形技术在美国尚未得到广泛应用。本研究旨在探讨 2011 年至 2016 年期间保乳术(部分乳房切除术)联合或不联合肿瘤整形技术的发病率趋势。
这是一项对 Optum Clinformatics 数据库(2010 年 1 月至 2017 年 3 月)中索赔数据的回顾性分析。在过去一年中没有接受过乳房手术的女性患者被分为三个独立的队列:单纯保乳术(Lx)、保乳术联合组织转移(LxTT)或保乳术联合乳房成形术和/或乳房提升术(LxMM)。肿瘤整形技术(在队列 2 和 3 中)可在初始保乳术时或 90 天随访时进行。
总体而言,19253 名患者符合纳入标准(91.1%为 Lx,5.2%为 LxTT,3.7%为 LxMM)。与接受肿瘤整形技术的患者相比,单纯行保乳术的患者具有乳腺癌家族史的比例显著较低(分别为 26.4%、33.7%和 37.9%;p<0.001)。2011 年至 2016 年,Lx 的发病率从 92.9%显著下降至 88.1%,而 LxTT 和 LxMM 的发病率从 4.2%增加至 7.2%和从 2.8%增加至 4.7%(均 p<0.001)。肿瘤整形技术的应用率最高的是太平洋地区(19.2%),而应用率最低的是东南中部地区(3.2%;p<0.001)。
尽管肿瘤整形技术的应用率有所增加,但复合年增长率仍低于 10%,且地区间差异显著。为了提高保乳术后的美容效果和患者满意度,有必要进一步采用肿瘤整形技术。